Literature DB >> 14662975

Molecular comparison of isolates of Burkholderia multivorans from patients with cystic fibrosis in the United Kingdom.

Jane F Turton1, Mary E Kaufmann, Nazim Mustafa, Sonia Kawa, Fiona E Clode, Tyrone L Pitt.   

Abstract

Burkholderia multivorans strains from 47 cystic fibrosis (CF) patients in 28 hospitals were compared by pulsed-field gel electrophoresis (PFGE) and flagellin (fliC) PCR-restriction fragment length polymorphism (PCR-RFLP) analysis. A considerable degree of genetic variation was evident, with each patient harboring a strain with a unique PFGE profile. Four sizes of fliC amplicons were produced, and these amplicons gave 13 RFLP types with restriction enzyme MspI. B. multivorans did not appear to spread between patients, suggesting that most CF patients acquire the organism from the natural environment.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14662975      PMCID： PMC308997          DOI： 10.1128/JCM.41.12.5750-5754.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  19 in total

Review 1.  Taxonomy and identification of the Burkholderia cepacia complex.

Authors:  T Coenye; P Vandamme; J R Govan; J J LiPuma
Journal:  J Clin Microbiol       Date:  2001-10       Impact factor: 5.948

2.  Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis.

Authors:  J J LiPuma; T Spilker; L H Gill; P W Campbell; L Liu; E Mahenthiralingam
Journal:  Am J Respir Crit Care Med       Date:  2001-07-01       Impact factor: 21.405

3.  Lack of evidence of nosocomial cross-infection by Burkholderia cepacia among Danish cystic fibrosis patients.

Authors:  H C Ryley; B Ojeniyi; N Høiby; J Weeks
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-09       Impact factor: 3.267

4.  Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates.

Authors:  C Segonds; T Heulin; N Marty; G Chabanon
Journal:  J Clin Microbiol       Date:  1999-07       Impact factor: 5.948

5.  DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III.

Authors:  E Mahenthiralingam; J Bischof; S K Byrne; C Radomski; J E Davies; Y Av-Gay; P Vandamme
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  Molecular epidemiology of cystic fibrosis-linked Burkholderia cepacia complex isolates from three national referral centres in Ireland.

Authors:  D Crowley; M Daly; B Lucey; P Shine; J J Collins; B Cryan; J E Moore; P Murphy; G Buckley; S Fanning
Journal:  J Appl Microbiol       Date:  2002       Impact factor: 3.772

7.  Transmission and prevalence of Burkholderia cepacia in Welsh cystic fibrosis patients.

Authors:  L Millar-Jones; H C Ryley; A Paull; M C Goodchild
Journal:  Respir Med       Date:  1998-02       Impact factor: 3.415

8.  The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain.

Authors:  L Sun; R Z Jiang; S Steinbach; A Holmes; C Campanelli; J Forstner; U Sajjan; Y Tan; M Riley; R Goldstein
Journal:  Nat Med       Date:  1995-07       Impact factor: 53.440

9.  Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland.

Authors:  T L Pitt; M E Kaufmann; P S Patel; L C Benge; S Gaskin; D M Livermore
Journal:  J Med Microbiol       Date:  1996-03       Impact factor: 2.472

10.  Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada.

Authors:  David P Speert; Deborah Henry; Peter Vandamme; Mary Corey; Eshwar Mahenthiralingam
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883
View more
  5 in total

1.  Revised approach for identification of isolates within the Burkholderia cepacia complex and description of clinical isolates not assigned to any of the known genomovars.

Authors:  Jane F Turton; Nazia Arif; Daneeta Hennessy; Mary E Kaufmann; Tyrone L Pitt
Journal:  J Clin Microbiol       Date:  2007-07-11       Impact factor: 5.948

2.  Transmission of Burkholderia cepacia complex: evidence for new epidemic clones infecting cystic fibrosis patients in Italy.

Authors:  S Campana; G Taccetti; N Ravenni; F Favari; L Cariani; A Sciacca; D Savoia; A Collura; E Fiscarelli; G De Intinis; M Busetti; A Cipolloni; A d'Aprile; E Provenzano; I Collebrusco; P Frontini; G Stassi; M Trancassini; D Tovagliari; A Lavitola; C J Doherty; T Coenye; J R W Govan; P Vandamme
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

3.  Species distribution and ribotype diversity of Burkholderia cepacia complex isolates from French patients with cystic fibrosis.

Authors:  Sylvain Brisse; Christophe Cordevant; Peter Vandamme; Philippe Bidet; Chawki Loukil; Gérard Chabanon; Marc Lange; Edouard Bingen
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

4.  Elucidating global epidemiology of Burkholderia multivorans in cases of cystic fibrosis by multilocus sequence typing.

Authors:  Adam Baldwin; Eshwar Mahenthiralingam; Pavel Drevinek; Chris Pope; David J Waine; Deborah A Henry; David P Speert; Phil Carter; Peter Vandamme; John J LiPuma; Chris G Dowson
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

5.  Genomics of an endemic cystic fibrosis Burkholderia multivorans strain reveals low within-patient evolution but high between-patient diversity.

Authors:  Cédric Lood; Charlotte Peeters; Quentin Lamy-Besnier; Jeroen Wagemans; Daniel De Vos; Marijke Proesmans; Jean-Paul Pirnay; Fedoua Echahidi; Denis Piérard; Matthieu Thimmesch; Anca Boeras; Katrien Lagrou; Evelien De Canck; Elke De Wachter; Vera van Noort; Rob Lavigne; Peter Vandamme
Journal:  PLoS Pathog       Date:  2021-03-15       Impact factor: 6.823
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.